Clinical Diagnostics News and Research

RSS

Merck Millipore announces joint development agreement with Sysmex Corporation

Merck Millipore, the Life Science division of Merck, today announced a clinical research, licensing and joint development agreement with Sysmex Corporation of Japan.

From Sysmex America, Inc. 18 Mar 2014

Covaris introduces truXTRAC High Throughput FFPE DNA Extraction & Purification Kit at 2014 AGBT

Covaris, Inc. introduced the truXTRAC™ High Throughput FFPE DNA Extraction & Purification Kit at the 2014 Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida.

11 Feb 2014

New collaboration aims to push cancer diagnostics to the next level

A collaboration between National Cancer Centre Singapore and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence. This new Centre facilitates the use of circulating tumour cells in clinical diagnostics, in order for new technologies to be applied by healthcare institutions.

19 Jan 2014

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

Frost & Sullivan released today its three big predictions for the global healthcare market. Based on a '2013 Search for Growth' survey which involved 1835 executives in more than 40 countries worldwide, Frost & Sullivan's insight highlights new areas of growth. mHealth, Cloud in Healthcare and Regulatory Environments will be the key subjects in 2014 and beyond.

4 Dec 2013

AB SCIEX launches IVD-MS Analyzer CE marked for general in vitro diagnostic use in Europe

Continuing to rapidly expand its presence in the clinical diagnostics field, AB SCIEX, a global leader in analytical technologies, today announced the launch of its AB SCIEX IVD-MS™ Analyzer CE marked for general in vitro diagnostic use in Europe.*

27 Nov 2013

Bruker receives FDA clearance to market MALDI Biotyper CA System in the U.S.

Bruker Corporation today announced that it has been granted U.S. FDA clearance under Section 510(k) to market its MALDI Biotyper CA System in the United States for the identification of Gram negative bacterial colonies cultured from human specimens.

26 Nov 2013

Pittcon to exhibit at BioConference Live’s “Cancer: Research, Discovery and Therapeutics” online-only event

Pittcon is pleased to announce it will be exhibiting at the next BioConference Live virtual event. BioConference Live, the largest producer of online-only conferences focused on life sciences, laboratory animal sciences and clinical diagnostics, has announced the upcoming “Cancer: Research, Discovery and Therapeutics” online-only conference.

26 Sep 2013

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

Companion diagnostics is critical in helping to pave the way for personalized medicine, in which the treatment is adapted and precisely tailored to the patient.

From Siemens Healthineers 27 Aug 2013

NanoString announces Early Access Program for nCounter Elements used in translational research

NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an Early Access Program for nCounter Elements™, a line of General Purpose Reagents (GPRs) developed specifically to meet the needs of translational research and clinical laboratories.

From NanoString Technologies 2 Aug 2013

Bruker introduces AVANCE-IVDr platform for NMR clinical research and screening

Bruker today announces a standardized nuclear magnetic resonance (NMR) spectroscopy platform for its clinical and diagnostics partners that enables cost-effective, high-performance NMR clinical screening and IVD-by-NMR discovery, development and validation of novel NMR assays.

24 Jul 2013

Solution-based circuit chip for rapid, multiplexed detection of pathogens

Life-threatening bacterial infections cause tens of thousands of deaths every year in North America. Increasingly, many infections are resistant to first-line antibiotics. Unfortunately, current methods of culturing bacteria in the lab can take days to report the specific source of the infection, and even longer to pinpoint the right antibiotic that will clear the infection.

13 Jun 2013

AB SCIEX launches 3200MD CE-IVDD series in Europe for in vitro diagnostic use

AB SCIEX, a global leader in analytical technologies, today announced the launch of the 3200MD CE-IVDD series for general in vitro diagnostic use in Europe.

20 May 2013

Exosome Diagnostics' urine exosome technology accurately predicts outcome of prostate biopsy

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcome of a prostate biopsy.

9 May 2013

BGI's second International Conference on Genomics in the Americas to be held in September

BGI, the world's largest genomics organization, will hold its second International Conference on Genomics in the Americas (ICG Americas 2013) on September 12-13, 2013 in Sacramento, CA.

17 Apr 2013

Matrix-Bio, Quest Diagnostics enter global licensing agreement for metabolomic biomarkers

Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.

From Quest Diagnostics 12 Apr 2013

New research to focus on sensors for advanced wound care

An innovative research agreement will put patients first in a bid to advance technology in the treatment and management of wounds - saving valuable time and money for health organisations throughout the world and helping to deliver safe and effective care.

14 Mar 2013

IntegraGen, Lab21 collaborate to develop new microRNA assay for colorectal cancer

Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.

22 Feb 2013

SV Bio, Mayo Clinic partner on whole genome diagnostics and interpretation

Mayo Clinic and Silicon Valley Biosystems (SV Bio) today announced a strategic collaboration for whole genome diagnostics and interpretation at the Mayo Clinic Center for Individualized Medicine and Mayo Medical Laboratories.

23 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012